| Date | Time | Room | Session Title | Presentation Time | Topic | Role |
|---|---|---|---|---|---|---|
| 15/04/2023 | 10:10 to 10:35 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Localized Disease |
10:10 to 10:30 | Adjuvant immunotherapy for high-risk renal carcinoma: how to explain discrepant results and what to do in practice | Speaker |
| 15/04/2023 | 10:10 to 10:35 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Localized Disease |
10:30 to 10:35 | Discussion | Discussant |
| 15/04/2023 | 10:50 to 12:10 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
10:50 to 11:05 | How to choose first-line treatment for metastatic renal cell carcinoma? I support the combination of immunotherapy (IO) plus TKI | Speaker |
| 15/04/2023 | 10:50 to 12:10 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
11:20 to 11:25 | Discussion | Discussant |
| 15/04/2023 | 10:50 to 12:10 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
12:05 to 12:10 | Discussion | Discussant |
| 15/04/2023 | 10:50 to 12:10 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
11:45 to 12:05 | Triplet therapy for metastatic renal cell carcinoma – current status and future directions | Speaker |
| 15/04/2023 | 12:35 to 13:00 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
12:35 to 12:55 | Novel agents and their mechanism of action on advanced renal cancer | Speaker |
| 15/04/2023 | 12:35 to 13:00 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
12:55 to 13:00 | Dicussion | Discussant |
| 15/04/2023 | 13:00 to 13:40 | Golden Hall |
Plenary Lecture - Clinical cases discussion: metastatic kidney cancer |
Discussant |